- Home
- NYC vs PMN Comparison
NYC vs PMN Comparison
Compare NYC & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYC
- PMN
- Stock Information
- Founded
- NYC 2013
- PMN 2004
- Country
- NYC United States
- PMN Canada
- Employees
- NYC N/A
- PMN N/A
- Industry
- NYC Real Estate
- PMN Pharmaceuticals and Biotechnology
- Sector
- NYC Finance
- PMN Health Care
- Exchange
- NYC Nasdaq
- PMN Nasdaq
- Market Cap
- NYC 27.6M
- PMN 23.9M
- IPO Year
- NYC N/A
- PMN N/A
- Fundamental
- Price
- NYC $11.10
- PMN $0.75
- Analyst Decision
- NYC
- PMN Strong Buy
- Analyst Count
- NYC 0
- PMN 1
- Target Price
- NYC N/A
- PMN $6.00
- AVG Volume (30 Days)
- NYC 6.5K
- PMN 26.2K
- Earning Date
- NYC 03-19-2025
- PMN 05-13-2025
- Dividend Yield
- NYC N/A
- PMN N/A
- EPS Growth
- NYC N/A
- PMN N/A
- EPS
- NYC N/A
- PMN 0.11
- Revenue
- NYC $61,570,000.00
- PMN N/A
- Revenue This Year
- NYC $8.40
- PMN N/A
- Revenue Next Year
- NYC $1.62
- PMN N/A
- P/E Ratio
- NYC N/A
- PMN $6.87
- Revenue Growth
- NYC N/A
- PMN N/A
- 52 Week Low
- NYC $5.46
- PMN $0.62
- 52 Week High
- NYC $12.52
- PMN $2.61
- Technical
- Relative Strength Index (RSI)
- NYC 64.21
- PMN 42.22
- Support Level
- NYC $10.04
- PMN $0.63
- Resistance Level
- NYC $12.48
- PMN $0.76
- Average True Range (ATR)
- NYC 0.68
- PMN 0.05
- MACD
- NYC 0.17
- PMN 0.00
- Stochastic Oscillator
- NYC 78.62
- PMN 40.94
About NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.